Sanofi Pasteur Commercializing MRSA Vaccine

The French vaccine maker announced a worldwide licensing agreement with the biotech company Syntiron to develop and commercialize its vaccine against staph, including Methicillin-resistant Staphylococcus aureus.

Sanofi Pasteur, the vaccines division of the Lyon, France-based sanofi-aventis Group, announced Wednesday it has entered into an exclusive, worldwide licensing agreement with Syntiron of St. Paul, Minn., to develop and commercialize its vaccine against staph, including Methicillin-resistant Staphylococcus aureus (MRSA), which is a major cause of health care-acquired infections.

Sanofi Pasteur will support the joint, pre-clinical development of the product and be responsible for all future developments, regulatory approval, and commercialization of the vaccine. "This agreement with Syntiron is just another example of Sanofi Pasteur's interest in partnering with biotechs to produce innovative vaccines to address public health needs," Sanofi Pasteur President/CEO Wayne Pisano said in the company's news release. "Along with our development of a vaccine to prevent Clostridium difficile infection, the successful development of a vaccine to prevent MRSA would be a major achievement in combating hospital-associated infections."

Citing the Internet Journal of Infectious Diseases, the release said MRSA accounts for as much as 40 percent of nosocomial (hospital-associated) staph infections in large U.S. hospitals and 25-30 percent in smaller hospitals. In Europe, its prevalence ranges from more than 50 percent in Portugal and Italy to below 2 percent in Switzerland and the Netherlands. Prevalence in Asia is about 50 percent, with high rates in Hong Kong (75 percent) and Japan (72 percent), and prevalence in African hospitals is estimated at 15 percent, with Kenya and Nigeria having the highest prevalence of 21-30 percent.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • The Top 5 Safety and Technology Trends to Watch

    Get the latest on trends you can expect to hear more about in 2019, including continued growth of mobile safety applications, wearable technology, and smart PPE; autonomous vehicles; pending OSHA recordkeeping rulemaking; and increased adoption of international safety standard, ISO 45001.

  • Analyze Incident Data

    Collect relevant incident data, analyze trends, and generate accurate regulatory reports, including OSHA 300, 300A, and 301 logs, through IndustrySafe’s extensive incident reporting and investigation module.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common training questions.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - January 2019

    January / February 2019


      Production vs. Safety 
      Meeting the Requirements for Emergency Equipment
      The State of Contractor Safety
      The Three Keys to Effective Chemical Management
    View This Issue